Latest Rabies Diagnostics Companies Update
Apr 2023: Denali Therapeutics Inc. and Biogen Inc. jointly announced that Denali's Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ) is now licensed, with Biogen having exercised that option. Alzheimer's disease is considered by the buildup of Aβ plaque in the brain. (AD). ATV:Aβ is intended to enhance brain exposure and target interaction of antibody therapies directed against Aβ, which may enable enhanced plaque clearance and decreased amyloid-related imaging abnormalities (ARIA). Denali's ATV platform is utilized to breach the blood-brain barrier (BBB). The option was used following a 2020 announcement of cooperation between Biogen and Denali. After the option is exercised, Biogen will oversee all research and development and any related costs. In addition to the one-time option exercise payment, Denali will be entitled to future royalties based on net sales and possible research and commercial milestone payments, provided specific criteria are met.
List of Rabies Diagnostics Key companies in the market
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- Aviva Systems Biology Corporation
- Creative Diagnostics
- Demeditec Diagnostics GmbH
- Abbexa Ltd.
- Norgen Biotek Corp.
- BioNote, Inc.
- Express Biotech International Inc.